Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Evaluating Phase & Product Appropriate Bioconjugate Development

Evaluating Phase & Product Appropriate Bioconjugate Development

11:30 am - Tuesday 13th October 2026

Exploring the differing development approaches of ADCs across the preclinical to commercial spectrum
Understanding how the bioconjugate landscape now encompasses a wide variety of modalities with differing MoAs and molecular structures
Exploring relevant examples of how the requirements for process and analytical development can vary between different conjugates

Speakers:

CONOR BARRY

CONOR BARRY

VP

Piramal Pharma Solutions